

Gianenrico Senna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9178919/publications.pdf>

Version: 2024-02-01

188
papers

8,185
citations

53794

45
h-index

56724

83
g-index

190
all docs

190
docs citations

190
times ranked

6559
citing authors

#	ARTICLE	IF	CITATIONS
1	Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. <i>Journal of Asthma</i> , 2022, 59, 1908-1913.	1.7	4
2	Proposal of 0.5Âmg of protein/100Âg of processed food as threshold for voluntary declaration of food allergen traces in processed foodâ€”A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GAA ² LEN position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1736-1750.	5.7	21
3	One-year mepolizumab for Allergic bronchopulmonary aspergillosis: Focus on steroid sparing effect and markers of response. <i>European Journal of Internal Medicine</i> , 2022, 99, 112-115.	2.2	7
4	Severe Asthma, Telemedicine, and Self-Administered Therapy: Listening First to the Patient. <i>Journal of Clinical Medicine</i> , 2022, 11, 960.	2.4	10
5	ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study. <i>Respiratory Research</i> , 2022, 23, 36.	3.6	14
6	Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. <i>Annals of Medicine</i> , 2022, 54, 869-874.	3.8	3
7	Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 713-721.	2.5	31
8	COVIDâ€“19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 871-874.	5.7	33
9	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1386-1388.	3.8	21
10	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. <i>Respiratory Medicine</i> , 2021, 176, 106261.	2.9	44
11	Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma. <i>Rheumatology</i> , 2021, 60, e59-e60.	1.9	11
12	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. <i>World Allergy Organization Journal</i> , 2021, 14, 100509.	3.5	14
13	COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. <i>World Allergy Organization Journal</i> , 2021, 14, 100517.	3.5	121
14	Effect of Î±1 antitrypsin deficiency on lung volume decline in severe asthmatic patients undergoing biologic therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1414-1416.	3.8	5
15	Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19. <i>Diagnostics</i> , 2021, 11, 507.	2.6	41
16	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274.	10.7	102
17	Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1036.	2.4	6
18	Biologics for Eosinophilic Granulomatosis With Polyangiitisâ€”One Size Does Not Fit All: Comment on the Article by Canzian et al. <i>Arthritis and Rheumatology</i> , 2021, 73, 1346-1347.	5.6	1

#	ARTICLE	IF	CITATIONS
19	Uncontrolled Asthma: Unmet Needs in the Management of Patients. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 457-466.	3.4	24
20	Anaphylaxis and Coronavirus Disease 2019 vaccine: a danger relationship?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 411-417.	2.3	5
21	Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?" <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2943-2944.	3.8	2
22	Anaphylaxis and Pregnancy: A Systematic Review and Call for Public Health Actions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4270-4278.	3.8	10
23	COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. <i>Vaccines</i> , 2021, 9, 853.	4.4	21
24	Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?. <i>Vaccines</i> , 2021, 9, 38.	4.4	19
25	Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 219.	2.9	31
26	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. <i>World Allergy Organization Journal</i> , 2021, 14, 100592.	3.5	17
27	The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19. <i>Clinical and Molecular Allergy</i> , 2021, 19, 19.	1.8	6
28	Comment on: Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma: reply. <i>Rheumatology</i> , 2021, 60, e79-e80.	1.9	0
29	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1460-1463.	5.7	16
30	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	3.5	30
31	Biologics for the Treatments of Allergic Conditions. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 549-564.	1.9	9
32	Asthmatic patients in COVID-19 outbreak: Few cases despite many cases. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 541-542.	2.9	40
33	<p>Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 599-604.	3.4	8
34	World Allergy Organization Anaphylaxis Guidance 2020. <i>World Allergy Organization Journal</i> , 2020, 13, 100472.	3.5	461
35	Oral health in asthmatic patients: a review. <i>Clinical and Molecular Allergy</i> , 2020, 18, 22.	1.8	31
36	Physicians's™ prescribing behaviour and clinical practice patterns for allergic rhinitis management in Italy. <i>Clinical and Molecular Allergy</i> , 2020, 18, 20.	1.8	4

#	ARTICLE	IF	CITATIONS
37	High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. <i>Thorax</i> , 2020, 75, 998-1000.	5.6	76
38	Editorial: Reconsidering anaphylaxis at the time of COVID-19 pandemic. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 429-430.	2.3	2
39	Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. <i>Clinical and Molecular Allergy</i> , 2020, 18, 8.	1.8	25
40	Low adherence to inhaled corticosteroids/long-acting β_2 -agonists and biologic treatment in severe asthmatics. <i>ERJ Open Research</i> , 2020, 6, 00017-2020.	2.6	12
41	Minimal clinically important difference for asthma endpoints: an expert consensus report. <i>European Respiratory Review</i> , 2020, 29, 190137.	7.1	72
42	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. <i>Respiratory Medicine</i> , 2020, 171, 106080.	2.9	28
43	Safety of uSCIT-MPL-4: prevalence and risk factors of systemic reactions in real life. <i>Immunotherapy</i> , 2019, 11, 783-794.	2.0	2
44	Trends and determinants of Emergency Room admissions for asthma: A retrospective evaluation in Northeast Italy. <i>World Allergy Organization Journal</i> , 2019, 12, 100046.	3.5	8
45	Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1205-1212.	2.5	25
46	One year of mepolizumab. Efficacy and safety in real-life in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101836.	2.6	57
47	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2539-2541.	5.7	36
48	Immunotherapy and biologicals for the treatment of allergy to Hymenoptera stings. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 919-925.	3.1	7
49	<p>New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic<p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 89-95.	3.2	8
50	Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. <i>World Allergy Organization Journal</i> , 2019, 12, 100007.	3.5	82
51	Time to revisit the definition and clinical criteria for anaphylaxis?. <i>World Allergy Organization Journal</i> , 2019, 12, 100066.	3.5	137
52	The Characteristics of Severe Chronic Upper-Airway Disease (SCUAD) in Patients with Allergic Rhinitis: A Real-Life Multicenter Cross-Sectional Italian Study. <i>International Archives of Allergy and Immunology</i> , 2019, 178, 333-337.	2.1	5
53	The Severe Asthma Network in Italy: Findings and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1462-1468.	3.8	112
54	Uncontrolled severe asthma: starting from the unmet needs. <i>Current Medical Research and Opinion</i> , 2019, 35, 175-177.	1.9	11

#	ARTICLE	IF	CITATIONS
55	Prevalence and features of asthmaâ€“chronic obstructive pulmonary disease overlap in Northern Italy general population. <i>Journal of Asthma</i> , 2019, 56, 27-33.	1.7	11
56	Sex in Respiratory and Skin Allergies. <i>Clinical Reviews in Allergy and Immunology</i> , 2019, 56, 322-332.	6.5	42
57	Omalizumab in elderly patients with chronic spontaneous urticaria: An Italian real-life experience. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 318-323.	1.0	21
58	Spontaneous pneumomediastinum complicating severe acute asthma exacerbation in adult patients. <i>Journal of Asthma</i> , 2018, 55, 1028-1034.	1.7	8
59	Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 208-218.	3.8	13
60	The Relevance of Nasal Cytology in the Workup of House Dust Mite-Induced Allergic Rhinitis. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 283.	2.9	2
61	Eosinophilic Granulomatosis With Polyangiitis and Cardiac Involvement: A Case Report. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 285-286.	1.3	1
62	Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 3.	1.8	15
63	The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. <i>Clinical and Molecular Allergy</i> , 2018, 16, 4.	1.8	17
64	Thunderstorm Asthma: A Critical Appraisal Based on Clinical Practice. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 273-275.	1.3	5
65	Allergic rhinitis: the eligible candidate to mite immunotherapy in the real world. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 11.	2.0	14
66	The role of the pharmacy in the management of bronchial asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 161-165.	1.0	10
67	Periostin: The bone and beyond. <i>European Journal of Internal Medicine</i> , 2017, 38, 12-16.	2.2	55
68	Serum periostin during omalizumab therapy in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 460-462.	1.0	6
69	Anaphylaxis and intimate behaviour. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 350-355.	2.3	11
70	SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. <i>Clinical and Molecular Allergy</i> , 2017, 15, 9.	1.8	36
71	Asthma management among allergists in Italy: results from a survey. <i>Clinical and Molecular Allergy</i> , 2017, 15, 11.	1.8	3
72	Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain. <i>World Allergy Organization Journal</i> , 2017, 10, 13.	3.5	17

#	ARTICLE	IF	CITATIONS
73	The relevance of house dust mites allergy in clinical practice: the epidemiological impact on allergen immunotherapy. <i>Immunotherapy</i> , 2017, 9, 1219-1224.	2.0	3
74	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. <i>Frontiers in Immunology</i> , 2017, 8, 242.	4.8	37
75	Evaluation of asthma control in the pharmacy: an Italian cross-sectional study. <i>European Annals of Allergy and Clinical Immunology</i> , 2017, 49, 225.	1.0	5
76	Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. <i>BMC Pulmonary Medicine</i> , 2016, 16, 128.	2.0	38
77	Therapeutic interventions in severe asthma. <i>World Allergy Organization Journal</i> , 2016, 9, 40.	3.5	38
78	Fatal asthma; is it still an epidemic?. <i>World Allergy Organization Journal</i> , 2016, 9, 42.	3.5	27
79	Scombroid syndrome: it seems to be fish allergy but... it isn't. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 516-521.	2.3	28
80	Wasp venom allergy screening with recombinant allergen testing. Diagnostic performance of rPol d 5 and rVes v 5 for differentiating sensitization to <i>Vespula</i> and <i>Polistes</i> subspecies. <i>Clinica Chimica Acta</i> , 2016, 453, 170-173.	1.1	27
81	What lies beyond Asthma Control Test: Suggestions for clinical practice. <i>Journal of Asthma</i> , 2016, 53, 559-562.	1.7	5
82	Allergic rhinitis: pharmacotherapy in pregnancy and old age. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1081-1089.	3.1	10
83	Phenotyping asthma in the elderly: allergic sensitization profile and upper airways comorbidity in patients older than 65 years. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 206-211.	1.0	10
84	Orphan immunotherapies for allergic diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 194-198.	1.0	8
85	Prospective adherence to specific immunotherapy in Europe (PASTE) survey protocol. <i>Clinical and Translational Allergy</i> , 2015, 5, 17.	3.2	6
86	Choosing wisely: practical considerations on treatment efficacy and safety of asthma in the elderly. <i>Clinical and Molecular Allergy</i> , 2015, 13, 7.	1.8	30
87	360 degree perspective on allergic rhinitis management in Italy: a survey of GPs, pharmacists and patients. <i>Clinical and Molecular Allergy</i> , 2015, 13, 25.	1.8	34
88	Asthma under/misdiagnosis in primary care setting: an observational community-based study in Italy. <i>Clinical and Molecular Allergy</i> , 2015, 13, 26.	1.8	17
89	Respiratory allergies in childhood: Recent advances and future challenges. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 702-710.	2.6	14
90	COPD prevalence in a north-eastern Italian general population. <i>Respiratory Medicine</i> , 2015, 109, 1040-1047.	2.9	27

#	ARTICLE	IF	CITATIONS
91	Omalizumab for severe allergic asthma in clinical trials and real-life studies: What we know and what we should address. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 28-35.	2.6	30
92	Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 31, 123-129.	2.6	47
93	Allergen Immunotherapy Adherence in the Real World: How Bad Is It and How Can It Be Improved?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 39-53.	2.2	23
94	Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 233-245.	3.0	17
95	The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners. <i>Clinical and Molecular Allergy</i> , 2015, 13, 4.	1.8	7
96	How far from correct is the use of adrenaline auto-injectors? A survey in Italian patients. <i>Internal and Emergency Medicine</i> , 2015, 10, 937-941.	2.0	19
97	Study on the Immunoreactivity of <i>Triticum monococcum</i> (Einkorn) Wheat in Patients with Wheat-Dependent Exercise-Induced Anaphylaxis for the Production of Hypoallergenic Foods. <i>Journal of Agricultural and Food Chemistry</i> , 2015, 63, 8299-8306.	5.2	17
98	Emerging drugs for allergic conjunctivitis. <i>Expert Opinion on Emerging Drugs</i> , 2014, 19, 291-302.	2.4	18
99	The level of control of mild asthma in general practice: an observational community-based study. <i>Journal of Asthma</i> , 2014, 51, 91-96.	1.7	14
100	Arguing the misconceptions in allergen-specific immunotherapy. <i>Immunotherapy</i> , 2014, 6, 587-595.	2.0	12
101	Update on the understanding, diagnosis and tailored management of anaphylaxis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 307-308.	2.3	2
102	Potential benefit of omalizumab in respiratory diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2014, 113, 513-519.	1.0	14
103	Dropouts in sublingual allergen immunotherapy trials – a systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 571-580.	5.7	31
104	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. <i>World Allergy Organization Journal</i> , 2014, 7, 6.	3.5	395
105	Omalizumab management beyond clinical trials: The added value of a network model. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 29, 74-79.	2.6	19
106	Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. <i>Allergy and Asthma Proceedings</i> , 2014, 35, 43-46.	2.2	6
107	A Survey of Clinical Features of Allergic Rhinitis in Adults. <i>Medical Science Monitor</i> , 2014, 20, 2151-2156.	1.1	12
108	Molecular diagnosis and the Italian Board for ISAC. <i>European Annals of Allergy and Clinical Immunology</i> , 2014, 46, 68.	1.0	7

#	ARTICLE	IF	CITATIONS
109	Illness perception, mood and coping strategies in allergic rhinitis: are there differences among ARIA classes of severity?. <i>Rhinology</i> , 2014, 52, 66-71.	1.3	10
110	The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1029-1033.	5.7	62
111	Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. <i>Clinical and Experimental Allergy</i> , 2013, 43, 22-28.	2.9	60
112	World Allergy Organization Anaphylaxis Guidelines: 2013 Update of the Evidence Base. <i>International Archives of Allergy and Immunology</i> , 2013, 162, 193-204.	2.1	241
113	Safety and tolerability of sublingual immunotherapy in clinical trials and real life. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 656-662.	2.3	30
114	Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1193-1195.	5.7	44
115	Balancing efficacy against safety in sublingual immunotherapy with inhalant allergens: what is the best approach?. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 937-947.	3.0	4
116	Immunological Treatments for Occupational Allergy. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 579-584.	2.1	9
117	2012 Update. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 389-399.	2.3	236
118	Shrimp Allergy in Italian Adults: A Multicenter Study Showing a High Prevalence of Sensitivity to Novel High Molecular Weight Allergens. <i>International Archives of Allergy and Immunology</i> , 2012, 157, 3-10.	2.1	30
119	<sc>R</sc>hin<sc>A</sc>sthma Patient Perspective: a short daily asthma and rhinitis <sc>Q</sc><sc>L</sc> assessment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1443-1450.	5.7	31
120	Type I variant of Kounis syndrome secondary to wasp sting. <i>Annals of Allergy, Asthma and Immunology</i> , 2012, 109, 79-81.	1.0	6
121	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. <i>Clinical and Translational Allergy</i> , 2012, 2, 20.	3.2	97
122	Research needs in allergy: an EAACI position paper, in collaboration with EFA. <i>Clinical and Translational Allergy</i> , 2012, 2, 21.	3.2	127
123	Patients with Asthma and Comorbid Allergic Rhinitis: Is Optimal Quality of Life Achievable in Real Life?. <i>PLoS ONE</i> , 2012, 7, e31178.	2.5	19
124	World Allergy Organization Guidelines for the Assessment and Management of Anaphylaxis. <i>World Allergy Organization Journal</i> , 2011, 4, 13-37.	3.5	642
125	Sensitization to Horse Allergens in Italy: A Multicentre Study in Urban Atopic Subjects without Occupational Exposure. <i>International Archives of Allergy and Immunology</i> , 2011, 155, 412-417.	2.1	27
126	Allergy and the bone: unexpected relationships. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 107, 202-206.	1.0	8

#	ARTICLE	IF	CITATIONS
127	World Allergy Organization anaphylaxis guidelines: Summary. Journal of Allergy and Clinical Immunology, 2011, 127, 587-593.e22.	2.9	491
128	Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone, 2011, 49, 880-885.	2.9	95
129	Are IgE Levels to Foods other than Rosaceae Predictive of Allergy in Lipid Transfer Protein-Hypersensitive Patients?. International Archives of Allergy and Immunology, 2011, 155, 149-154.	2.1	26
130	An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 375-380.	2.3	17
131	Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA2LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 840-844.	5.7	72
132	Anisakis hypersensitivity in Italy: prevalence and clinical features: a multicenter study. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1563-1569.	5.7	49
133	Food-Specific IgG4 Lack Diagnostic Value in Adult Patients with Chronic Urticaria and Other Suspected Allergy Skin Symptoms. International Archives of Allergy and Immunology, 2011, 155, 52-56.	2.1	14
134	Allergy immunotherapy tablet: Grazax [®] for the treatment of grass pollen allergy. Expert Review of Clinical Immunology, 2011, 7, 21-27.	3.0	16
135	Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA ² LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 290-295.	5.7	92
136	Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA ² LEN taskforce position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 959-968.	5.7	62
137	Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors?. Journal of Allergy and Clinical Immunology, 2010, 125, 1171.	2.9	13
138	How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. Journal of Allergy and Clinical Immunology, 2010, 126, 668-669.	2.9	95
139	Causes of Food-Induced Anaphylaxis in Italian Adults: A Multi-Centre Study. International Archives of Allergy and Immunology, 2009, 150, 271-277.	2.1	118
140	EpidemAAITO: Features of food allergy in Italian adults attending allergy clinics: a multi-centre study. Clinical and Experimental Allergy, 2009, 39, 547-555.	2.9	108
141	A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clinical and Experimental Allergy, 2009, 39, 1569-1574.	2.9	47
142	Administration regimens for sublingual immunotherapy to pollen allergens: What do we know?. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 849-854.	5.7	46
143	How much specific is the association between hymenoptera venom allergy and mastocytosis?. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1379-1382.	5.7	79
144	Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. Journal of Allergy and Clinical Immunology, 2009, 123, 680-686.	2.9	360

#	ARTICLE	IF	CITATIONS
145	Evidence of adherence to allergen-specific immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 544-548.	2.3	78
146	Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 256-257.	2.9	67
147	Comparison of costs of sublingual immunotherapy and drug treatment in grass-pollen induced allergy: results from the SIMAP database study. <i>Current Medical Research and Opinion</i> , 2008, 24, 261-266.	1.9	36
148	Standardization of Skin Tests for Diagnosis and Prevention of Hypersensitivity Reactions to Oxaliplatin. <i>International Archives of Allergy and Immunology</i> , 2008, 145, 54-57.	2.1	34
149	The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy. <i>International Archives of Allergy and Immunology</i> , 2008, 147, 231-234.	2.1	18
150	Is hymenoptera venom allergy an occupational disease?. <i>Occupational and Environmental Medicine</i> , 2008, 65, 217-218.	2.8	8
151	Intimate behavior and allergy: a narrative review. <i>Annals of Allergy, Asthma and Immunology</i> , 2007, 99, 394-400.	1.0	36
152	Correlation among FEV1, nitric oxide and asthma control test in newly diagnosed asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 207-8.	5.7	33
153	Evaluation of the IgE cross-reactions among vespid venoms. A possible approach for the choice of immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 561-564.	5.7	59
154	Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 966-967.	5.7	11
155	Relationship between ARIA classification and drug treatment in allergic rhinitis and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1064-1070.	5.7	33
156	Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: Evaluation of A novel SLIT formulation during a Year). <i>Pediatric Allergy and Immunology</i> , 2007, 18, 58-62.	2.6	57
157	Allergic rhinitis and asthma comorbidity: ARIA classification of rhinitis does not correlate with the prevalence of asthma. <i>Clinical and Experimental Allergy</i> , 2007, 37, 954-960.	2.9	56
158	Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. <i>Annals of Allergy, Asthma and Immunology</i> , 2006, 97, 615-621.	1.0	62
159	Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 946-948.	2.9	51
160	Specific immunotherapy among Italian specialists. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 898-899.	5.7	6
161	Improving quality of life as an optimal goal of allergen immunotherapy. <i>Clinical and Experimental Allergy Reviews</i> , 2006, 6, 61-61.	0.3	0
162	Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. <i>European Annals of Allergy and Clinical Immunology</i> , 2006, 38, 31-4.	1.0	17

#	ARTICLE	IF	CITATIONS
163	Are Physicians Aware of the Side Effects of Angiotensin-Converting Enzyme Inhibitors?. Chest, 2005, 128, 976-979.	0.8	27
164	Latex-jujube cross-reactivity: case report and immunological study. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 971-972.	5.7	2
165	Pattern of use and diagnostic value of complementary/alternative tests for adverse reactions to food. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 1216-1217.	5.7	11
166	In chronic idiopathic urticaria autoantibodies against FcεRI/CD23 induce histamine release via eosinophil activation. Clinical and Experimental Allergy, 2005, 35, 1599-1607.	2.9	87
167	Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. Journal of Allergy and Clinical Immunology, 2004, 113, 643-649.	2.9	85
168	Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services. Journal of Allergy and Clinical Immunology, 2003, 111, 1410-1412.	2.9	24
169	Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. Journal of the American Academy of Dermatology, 2003, 49, 714-716.	1.2	44
170	Dermatological powder as hidden cause of occupational allergy due to casein: a case report. Occupational and Environmental Medicine, 2003, 60, 609-610.	2.8	8
171	Anaphylaxis due to carrot as hidden food allergen. Allergologia Et Immunopathologia, 2002, 30, 243-244.	1.7	9
172	Double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. Clinical and Experimental Allergy, 2002, 32, 928-932.	2.9	37
173	The natural history of respiratory allergy: A follow-up study of 99 patients up to 10 years. Respiratory Medicine, 2001, 95, 9-12.	2.9	54
174	Cold-Induced Rhinitis in Skiers—Clinical Aspects and Treatment with Ipratropium Bromide Nasal Spray: A Randomized Controlled Trial. American Journal of Rhinology & Allergy, 2001, 15, 297-301.	2.2	38
175	Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1091-1095.	5.7	64
176	Exercise-induced anaphylaxis to grape. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 1235-1236.	5.7	18
177	The role of patient training in the management of seasonal rhinitis and asthma: clinical implications. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 65-68.	5.7	44
178	Health-related quality of life assessment in young adults with seasonal allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2001, 56, 313-317.	5.7	61
179	Is alternative medicine acceptable in allergology?. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 1200-1200.	5.7	7
180	A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 1999, 54, 1173-1180.	5.7	33

#	ARTICLE	IF	CITATIONS
181	Unconventional medicine: a risk of undertreatment of allergic patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 1117-1119.	5.7	11
182	Prevalence of latex-specific IgE in blood donors: an Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1999, 54, 80-81.	5.7	14
183	Likelihood ratios and Fagan's nomogram: valuable but underrated tools for in vitro latex sensitization assessment. <i>Clinica Chimica Acta</i> , 1999, 282, 175-183.	1.1	6
184	Pizza, an unsuspected source of soybean allergen exposure. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 1106-1107.	5.7	8
185	Nimesulide reduces skin-test reactivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1997, 52, 596-596.	5.7	1
186	Clinical efficacy and safety of local nasal immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1997, 52, 36-39.	5.7	10
187	Local nasal immunotherapy with extract in powder form is effective and safe in grass pollen rhinitis: A double-blind study. <i>Journal of Allergy and Clinical Immunology</i> , 1996, 97, 34-41.	2.9	61
188	Local nasal immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1995, 50, 190-190.	5.7	7